Tonsillectomy Plus Immunosuppression Improves Outcomes in High-Risk IgA Nephropathy Among Caucasians

Editor's Note: The following study results were first published in Nephrology Dialysis Transplantation (December 16, 2025) and later shared in the Oxford Academic. The original study authors are Zinaida S.…

Continue Reading Tonsillectomy Plus Immunosuppression Improves Outcomes in High-Risk IgA Nephropathy Among Caucasians

Breaking Into a Crowded Market: Otsuka’s Pioneering APRIL Inhibitor Marks New Era in Kidney Disease Treatment

Otsuka has claimed a significant victory in the increasingly competitive immunoglobulin A nephropathy (IgAN) field with FDA accelerated approval of Voyxact, the first-in-class anti-APRIL biologic therapy designed to treat this…

Continue Reading Breaking Into a Crowded Market: Otsuka’s Pioneering APRIL Inhibitor Marks New Era in Kidney Disease Treatment

FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer…

Continue Reading FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

When AI Sees What Radiologists Miss: How Artificial Intelligence is Reshaping Breast Cancer Detection

A groundbreaking study from Massachusetts General Hospital reveals that artificial intelligence is catching breast cancers that skilled radiologists initially overlook. As reported by Business Wire, Hologic's Genius AI Detection solution…

Continue Reading When AI Sees What Radiologists Miss: How Artificial Intelligence is Reshaping Breast Cancer Detection

GENESIS Pharma Secures Exclusive Rights to Donidalorsen for Hereditary Angioedema in CEE

As reported on PharmaBiz, GENESIS Pharma has announced an exclusive agreement with Otsuka Pharmaceutical Europe Ltd. (OPEL) to distribute and commercialize donidalorsen across 14 Central and Eastern European countries, including…

Continue Reading GENESIS Pharma Secures Exclusive Rights to Donidalorsen for Hereditary Angioedema in CEE

Renalys Pharma Announces Positive Phase III Results for Sparsentan in Japanese IgA Nephropathy Patients

As reported on PharmaBiz, Renalys Pharma has reported encouraging topline data from its Phase III trial evaluating sparsentan (RE-021), an oral dual endothelin and angiotensin II receptor antagonist, in Japanese…

Continue Reading Renalys Pharma Announces Positive Phase III Results for Sparsentan in Japanese IgA Nephropathy Patients